

The main activities of the Working Party during the year are summarised here:

The working party was reformed in March 2006 and has met once in July 2006 to review the working party remit and prioritise work.

Initial work will be;

- The data collected by the NHD will be reviewed and different data sets will be collected for patients developing an inhibitor either before or after 150 exposure days.
- Further investigation of risk factors for inhibitor formation in PUPs and MTPs
- Retrospectively review data relating to product changes and inhibitor risk.
- Consider prospective international collaboration to investigate product changes and inhibitor risk.
- Collate data on use of rituximab in congenital and acquired haemophilia in UK

Publications

Guidelines produced under the previous working party have been published this year.

Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006 Jun;133(6):591-605

The UKHCDO acquired haemophilia study has been accepted for publication in Blood.

Dr Peter Collins
August 2006